2025
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatientsDiagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosis
2024
BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES. Neuro-Oncology 2024, 26: viii38-viii38. PMCID: PMC11552887, DOI: 10.1093/neuonc/noae165.0151.Peer-Reviewed Original ResearchPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETRituximab-based therapyRituximab-based treatmentMedian overall survivalNon-Hodgkin's lymphomaManifestation of malignancyNervous systemTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseSystematic reviewProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationClinical presentationClinical Presentation, Management, and Outcome in Neurolymphomatosis
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. Clinical Presentation, Management, and Outcome in Neurolymphomatosis. Neurology 2024, 103: e209698. PMID: 39102613, DOI: 10.1212/wnl.0000000000209698.Peer-Reviewed Original ResearchConceptsPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETMedian overall survivalRituximab-based therapyRituximab-based treatmentNon-Hodgkin's lymphomaManifestation of malignancyNervous systemLog-rank testTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseIndividual patient dataProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationKeratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Delgado-Coka L, Roa-Peña L, Babu S, Horowitz M, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Akalin A, Jiang W, Larson B, Hendifar A, Picozzi V, Choi M, Shroyer K, Escobar-Hoyos L. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal Of Clinical Pathology 2024, 162: 314-326. PMID: 38642081, PMCID: PMC11369068, DOI: 10.1093/ajcp/aqae038.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPredictive biomarkersDuctal adenocarcinomaK17 expressionKeratin 17Gemcitabine-based therapyGemcitabine-based chemotherapyBasal molecular subtypeTumor mutation statusResponse to chemotherapyPancreatic ductal adenocarcinoma cellsThreshold of expressionChemotherapeutic regimensAdvanced-stageClinicopathological variablesMutation statusPrognostic stratificationMolecular subtypesShorter survivalLonger survivalFormalin-fixedImmunohistochemical testsPredictive valuePatientsTherapeutic interventions
2021
Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine
Buza N, Hui P. Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine. Modern Pathology 2021, 34: 1658-1672. PMID: 34088998, DOI: 10.1038/s41379-021-00831-9.Peer-Reviewed Original ResearchConceptsGestational trophoblastic diseaseTrophoblastic diseaseGestational trophoblastic tumorsGestational trophoblastic neoplasiaRoutine diagnostic workupDNA genotypingSignificant clinical relevancePowerful ancillary toolFIGO/Genetic zygosityGestational eventIndex gestationTrophoblastic tumorTrophoblastic neoplasiaGestational choriocarcinomaPrognostic stratificationDiagnostic workupPrognostic assessmentClinical relevanceClinical practiceGestational originMolecular diagnostic capabilitiesPatient careSporadic hydatidiformCopy number alterations
2019
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 2019, 139: 124-132. PMID: 31778960, DOI: 10.1016/j.lungcan.2019.11.013.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePleural effusionMPM patientsPleural mesotheliomaPrognostic stratificationNon-epithelioid malignant pleural mesotheliomaStage IV lung cancerEpithelioid malignant pleural mesotheliomaInferior overall survivalTGF-β levelsLevels of TGFLung cancer patientsChest CT scanOverall survivalSMRP levelsClinicopathological characteristicsDismal prognosisPleural diseaseTumor loadAggressive malignancyDisease stageCancer patientsLung cancerPrimary diagnosisDebates over NICE Guideline Update: What Are the Roles of Nuclear Cardiology in the Initial Evaluation of Stable Chest Pain?
Cho S, Kim J, Song H. Debates over NICE Guideline Update: What Are the Roles of Nuclear Cardiology in the Initial Evaluation of Stable Chest Pain? Nuclear Medicine And Molecular Imaging 2019, 53: 301-312. PMID: 31723359, PMCID: PMC6821897, DOI: 10.1007/s13139-019-00607-9.Peer-Reviewed Original ResearchNuclear myocardial perfusion imagingStable chest painMyocardial perfusion imagingEvaluation of stable chest painNational Institute for Health and Care ExcellenceCardiac computed tomographyChest painCardiac CTPre-test probabilityNational Institute for Health and Care Excellence guidelinesCoronary artery diseaseSecond-line studiesCardiac testingPrognostic stratificationNuclear physiciansGuideline updatePerfusion imagingArtery diseaseClinical trialsPainTreatment decisionsNuclear cardiologyCT trialsInitial evaluationCare Excellence
2016
Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer
Deloria AJ, Höflmayer D, Kienzl P, Łopatecka J, Sampl S, Klimpfinger M, Braunschmid T, Bastian F, Lu L, Marian B, Stättner S, Holzmann K. Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer. Oncotarget 2016, 5: 73800-73816. PMID: 27650542, PMCID: PMC5342015, DOI: 10.18632/oncotarget.12070.Peer-Reviewed Original ResearchConceptsColorectal cancerEpithelial-mesenchymal transitionPrognostic valueNon-neoplastic colorectal epitheliumPrognosis of CRCFavorable overall survivalHuman colorectal cancerRole of ESRP1Overall survivalCRC casesPathological stageCRC cellsPrognostic stratificationFavorable outcomeTumor stagingClinical dataTCGA cohortColorectal epitheliumTumor progressionMicrosatellite instabilityMicrosatellite stabilityTumor cellsEarly detectionProtein 1Tissue expression
2014
Gastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye H, Strosberg J, Baudin E, Klimstra D, Yao J. Gastroenteropancreatic high‐grade neuroendocrine carcinoma. Cancer 2014, 120: 2814-2823. PMID: 24771552, DOI: 10.1002/cncr.28721.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyNeuroendocrine carcinomaGEP-NECKi-67High-grade neuroendocrine carcinomaKi-67 proliferation indexCell neuroendocrine carcinomaSmall cell carcinomaGastroenteropancreatic (GEPHigh-grade tumorsKi-67 indexProliferation rateLong-term survivalIntermediate-gradeLocalized diseaseNeuroendocrine neoplasmsPrognostic stratificationCell carcinomaProliferation indexTreatment optionsOptimal treatmentLow-gradeTumorChemotherapyPatients
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
2008
Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma
Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma. Journal Of Clinical Oncology 2008, 27: 271-278. PMID: 19064983, DOI: 10.1200/jco.2008.17.0043.Peer-Reviewed Original ResearchConceptsThyroid transcription factor-1Stage I lung adenocarcinomaTTF1 expressionTranscription factor 1Lung adenocarcinomaStage IIndependent lower riskMedian overall survivalProtein expressionIndependent prognostic factorPotential prognostic parametersSubgroup of patientsFactor 1Overall survivalPrognostic factorsPatient survivalPrognostic parametersPrognostic stratificationLung cancerFavorable outcomeSitu protein expressionIndependent cohortLower riskPatientsAdenocarcinoma
2001
Utility of prognostic stratification in adults with community-acquired bacterial meningitis
Aronin S, Quagliarello V. Utility of prognostic stratification in adults with community-acquired bacterial meningitis. Comprehensive Therapy 2001, 27: 72-77. PMID: 11280860, DOI: 10.1007/s12019-001-0011-7.Peer-Reviewed Original Research
1999
A prognostic rule for elderly patients admitted with community-acquired pneumonia
Conte H, Chen Y, Mehal W, Phil D, Scinto J, Quagliarello V. A prognostic rule for elderly patients admitted with community-acquired pneumonia. The American Journal Of Medicine 1999, 106: 20-28. PMID: 10320113, DOI: 10.1016/s0002-9343(98)00369-6.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaElderly patientsDerivation cohortValidation cohortStaging systemHeterogeneous adult populationAdult populationHospital mortality ratePrognostic staging systemVital sign abnormalitiesHospital mortalityCreatinine levelsIndependent predictorsMultivariable analysisPrognostic stratificationAdmission characteristicsPneumoniaMortality ratePatientsCohortPrognostic rulesMotor responseMortalityGreater overall accuracyAdmission
1995
Prognostic Stratification in Critically Ill Patients With Acute Renal Failure Requiring Dialysis
Chertow G, Christiansen C, Cleary P, Munro C, Lazarus J. Prognostic Stratification in Critically Ill Patients With Acute Renal Failure Requiring Dialysis. JAMA Internal Medicine 1995, 155: 1505-1511. PMID: 7605152, DOI: 10.1001/archinte.1995.00430140075007.Peer-Reviewed Original ResearchConceptsAcute renal failureHospital mortalityRenal failureIll patientsMechanical ventilationAcute Renal Failure Requiring DialysisIntensive care unit technologyMultivariate logistic regression analysisCritically Ill PatientsHospital mortality rateHigh-risk patientsOrgan system failureIntensive care unitLogistic regression analysisOminous conditionUnderlying malignancyHospital dischargeConsecutive patientsCare unitComorbid conditionsLaboratory variablesEarly mortalityPrognostic stratificationMedical recordsProspective validation
1994
Effect of athletic training on heart rate variability
Sacknoff D, Gleim G, Stachenfeld N, Coplan N. Effect of athletic training on heart rate variability. American Heart Journal 1994, 127: 1275-1278. PMID: 8172056, DOI: 10.1016/0002-8703(94)90046-9.Peer-Reviewed Original ResearchConceptsHeart rate variabilityRate variabilityParasympathetic toneControl subjectsHeart diseaseVagal activityBaseline parasympathetic toneCardiac vagal toneFrequency domain variablesChronic exerciseHabitual exercisePrognostic stratificationVagal toneControl groupEndurance athletesActivity levelsPatientsAthletic trainingAthletesDiseaseToneExerciseAccurate indicatorSubjectsPrognosis
1981
Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.
Cohen M, Makuch R, Johnston-Early A, Ihde D, Bunn P, Fossieck B, Minna J. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Journal Of The National Cancer Institute 1981, 65: 187-95. PMID: 6263468.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLaboratory parametersLung cancerPerformance statusPrognostic factorsPrognostic indexSmall cell anaplastic lung cancerInfluential prognostic factorObjective prognostic indexPretreatment performance statusMajor prognostic factorSelf-limited eventAlpha-1 globulinCancer clinical trialsLaboratory resultsSignificant prognosticatorMedian followupAlbumin levelsMinimum followupPrognostic stratificationSurvival durationClinical trialsHigher hemoglobinTreatment response
1980
Thallium-201 myocardial scintigraphy in acute myocardial infarction and ischemia
Wackers F. Thallium-201 myocardial scintigraphy in acute myocardial infarction and ischemia. Seminars In Nuclear Medicine 1980, 10: 127-145. PMID: 7394537, DOI: 10.1016/s0001-2998(80)80016-x.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionPerfusion defectsThallium-201 myocardial scintigraphyThallium-201 scintigraphyOnset of symptomsResults of scintigraphyChest painUnstable anginaJeopardized myocardiumMyocardial scintigraphyPrognostic stratificationEarly recognitionHigh riskInfarctionPatientsScintigraphyIschemiaHrAnginaComplicationsPainReliable method
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply